Business
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
POTOMAC, MD / ACCESS Newswire / January 6, 2026 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / January 6, 2026 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that its Board of Directors has approved a change in the Company's fiscal year end from March 31 to December 31, effective December 31, 2025.","length":461,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":624,"height":369,"url":"https://media.zenfs.com/en/accesswire.ca/0e2af139eaf45e7d389d700466cbdb1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/w86PvbhiDg_0NVcYSpdK.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/0e2af139eaf45e7d389d700466cbdb1a","width":624,"height":369}},"href":"https://app.accessnewswire.com/imagelibrary/287ff0ce-682f-4806-b573-b41062ae3651/1124322/igcpharma-logo.jpg","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""This is a straightforward but important step in strengthening how we engage with U.S. investors," said Ram Mukunda, CEO of IGC Pharma. "Aligning our fiscal year with the calendar year improves clarity, comparability, and accessibility of our financial reporting. As we continue advancing our clinical and AI-driven programs, we want our reporting structure to reflect the standards and expectations of the U.S. public markets."","length":448,"tagName":"p"},{"type":"text","content":"The change is intended to enhance transparency, improve comparability with U.S.-listed peers, and simplify financial analysis for investors and analysts by aligning IGC Pharma's reporting calendar with the standard calendar year used by most U.S. public companies. The alignment also supports more consistent communication with the U.S. capital markets as the Company advances its clinical programs and long-term growth strategy.","length":433,"tagName":"p"},{"type":"text","content":"As a result of this change, IGC Pharma will file a transition report on Form 10-K with the U.S. Securities and Exchange Commission (the "SEC") covering the nine-month period from April 1, 2025, thr...